Weighing the risk of hemolytic disease of the newborn versus the benefits of using of RhD-positive blood products in trauma.

Andrews, Jennifer; Josephson, Cassandra D; Young, Pampee; Spinella, Philip C; Yazer, Mark H

Andrews, Jennifer; Josephson, Cassandra D; Young, Pampee; Spinella, Philip C; Yazer, Mark H.

Afiliación

Andrews J; Department of Pathology, Microbiology and Immunology, Division of Transfusion Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Josephson CD; Department of Pediatrics, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Young P; Cancer and Blood Disorders Institute, Blood Bank and Transfusion Medicine, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.
Spinella PC; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yazer MH; Department of Pathology, Microbiology and Immunology, Division of Transfusion Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Transfusion ; 63 Suppl 3: S4-S9, 2023 05.

Article en En | MEDLINE | ID: mdl-37070798

Asunto(s)

Eritroblastosis Fetal; Recién Nacido; Humanos; Femenino; Sistema del Grupo Sanguíneo Rh-Hr

Palabras clave

RhD; hemolytic disease of the fetus and newborn; low titer group O whole blood; massive bleeding; mismatch; red blood cell; safety; trauma; women

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Eritroblastosis Fetal Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans / Newborn Idioma: En Revista: Transfusion Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google